Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides calories and serves as a source of glucose for cellular metabolism. Sodium chloride and potassium chloride are electrolytes that restore and maintain fluid and electrolyte balance. Potassium is essential for nerve conduction, muscle contraction, and acid-base balance. Sodium is the main cation of extracellular fluid and regulates fluid balance, while chloride is the main anion.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Intravenous infusion for fluid and electrolyte replenishment in patients who require maintenance or replacement of fluids, electrolytes, and calories,Correction of hypokalemia when combined with potassium supplementation,Parenteral nutrition as a source of carbohydrates and electrolytes
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; adult dose determined by fluid, electrolyte, and caloric needs. Typical administration rate: 1-2 liters per day at 100-200 m L/hour, not to exceed 0.5 g/kg/hour dextrose and 0.5 m Eq/kg/hour potassium. Maximum potassium infusion rate: 10 m Eq/hour (or 0.5 m Eq/kg/hour).
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Glucose: ~30 minutes (metabolic clearance). Potassium: distribution half-life 1 hour, elimination half-life ~12 hours (renal-dependent). Sodium/chloride: rapidly equilibrated, with elimination half-life determined by renal function.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the citric acid cycle to produce energy. Sodium and potassium are not metabolized but are excreted renally. Chloride is also reabsorbed and excreted by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Electrolytes (sodium, chloride, potassium) are primarily excreted renally; glucose is metabolized to CO2 and water, with minimal renal excretion of unchanged glucose (<1% in normoglycemia). Biliary/fecal elimination is negligible for individual components.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Glucose: minimal (<10% bound to albumin). Potassium: not protein bound. Sodium/chloride: not protein bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Glucose: Vd 0.2–0.3 L/kg (restricted to extracellular fluid). Potassium: Vd 0.5–0.7 L/kg (distributes in total body water, with higher intracellular uptake). Sodium/chloride: Vd 0.2–0.3 L/kg (extracellular fluid).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% (only route of administration).
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
For GFR 30-50 m L/min: reduce potassium content or infusion rate; monitor potassium levels closely. For GFR <30 m L/min: contraindicated unless potassium levels and ECG are monitored; consider potassium-free alternatives. Anuria: contraindicated.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh Class A and B: no specific adjustment needed; monitor potassium and glucose levels. Child-Pugh Class C: use with caution; monitor for hyperkalemia and fluid overload; reduce potassium infusion rate if necessary.
No dosage adjustment required for hepatic impairment.
Weight-based dose: 100-150 m L/kg/day for maintenance; potassium dose: 2-4 m Eq/kg/day, not to exceed 0.5 m Eq/kg/hour. Maximum dextrose infusion rate: 0.5 g/kg/hour. Adjust for fluid and electrolyte deficits.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Lower starting doses due to decreased renal function; monitor renal function, potassium, and glucose levels closely. Avoid excessive fluid administration; typical rate: 50-100 m L/hour initially, adjust based on clinical response and serum electrolytes.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
NOT FOR USE IN NEONATES OR INFANTS LESS THAN 1 MONTH OF AGE CONTAINING BENZYL ALCOHOL AS PRESERVATIVE (not applicable to this product as it is preservative-free). Also, solutions containing potassium chloride must be administered with caution due to risk of hyperkalemia and cardiac arrest from rapid infusion.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hyperglycemia, especially in patients with diabetes mellitus,Risk of hyperkalemia with rapid infusion or in patients with renal impairment,Fluid overload in patients with heart failure or renal impairment,Electrolyte imbalances including hypernatremia or hyponatremia,Extravasation may cause tissue damage,Use with caution in patients with severe renal impairment, metabolic alkalosis, or respiratory alkalosis
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperkalemia,Hypernatremia,Severe metabolic alkalosis,Anuria or severe renal impairment,Presence of elevated blood urea nitrogen (BUN) due to extrarenal causes,Patients with known hypersensitivity to any component
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No direct food interactions with intravenous administration. However, patients should maintain a balanced diet as per their underlying condition; potassium-rich foods may need to be considered if oral intake is resumed.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Teratogenic risk is low due to the physiological nature of components. Dextrose and electrolytes are essential nutrients; potassium at 20 m Eq is within standard supplementation range. No increased risk of major malformations reported in any trimester. However, careful monitoring is required in cases of maternal hyperglycemia or electrolyte imbalances, which may indirectly affect fetal development.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Dextrose, sodium, chloride, and potassium are normal constituents of breast milk. Intravenous administration does not significantly alter milk composition. M/P ratio not applicable as these are endogenous substances. Considered compatible with breastfeeding; no expected adverse effects on the nursing infant.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy-induced plasma volume expansion and increased glomerular filtration rate may alter electrolyte requirements. Dose adjustments are generally not required for dextrose and electrolytes at standard concentrations. However, potassium dose may need adjustment in preeclampsia or renal impairment. Close monitoring of serum potassium and glucose is recommended, with titration based on maternal levels.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This combination is used for maintenance hydration and correction of electrolyte deficits. Do not administer unless solution is clear and container undamaged. Monitor serum potassium levels and renal function; risk of hyperkalemia if renal impairment or rapid infusion. Infuse via central line if concentration >10% dextrose. Use with caution in patients with heart failure or edema due to sodium load.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This solution is given intravenously to provide fluids, sugar, and potassium.,Tell your healthcare provider if you have kidney disease, high potassium levels, or heart problems.,Report any swelling, shortness of breath, or irregular heartbeat while receiving this infusion.,Inform your doctor if you are pregnant, breastfeeding, or taking any potassium-sparing diuretics or ACE inhibitors.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides calories and serves as a source of glucose for cellular metabolism. Sodium chloride and potassium chloride are electrolytes that restore and maintain fluid and electrolyte balance. Potassium is essential for nerve conduction, muscle contraction, and acid-base balance. Sodium is the main cation of extracellular fluid and regulates fluid balance, while chloride is the main anion.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER is: Intravenous infusion; adult dose determined by fluid, electrolyte, and caloric needs. Typical administration rate: 1-2 liters per day at 100-200 m L/hour, not to exceed 0.5 g/kg/hour dextrose and 0.5 m Eq/kg/hour potassium. Maximum potassium infusion rate: 10 m Eq/hour (or 0.5 m Eq/kg/hour).. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER is classified as Category A/B. Teratogenic risk is low due to the physiological nature of components. Dextrose and electrolytes are essential nutrients; potassium at 20 mEq is within standard supplementation ran. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.